Parata Systems, LLC provides pharmacy automation solutions in the United States. Its products include Parata Max, a pharmacy automation solution; Parata Mini, which automates counting for drugs; Parata APM, a self-service prescription pick up solution; and onePAC packaging, a compliance unit- and multi-dose packaging solution. The company also offers installation and training solutions. Its products are used for dispensing drugs in retail pharmacies. The company was founded in 2001 and is headquartered in Durham, North Carolina.

Parata Systems, LLC provides pharmacy automation solutions in the United States. Its products include Parata Max, a pharmacy automation solution; Parata Mini, which automates counting for drugs; Parata APM, a self-service prescription pick up solution; and onePAC packaging, a compliance unit- and multi-dose packaging solution. The company also offers installation and training solutions. Its products are used for dispensing drugs in retail pharmacies. The company was founded in 2001 and is headquartered in Durham, North Carolina.

Blueprint Genetics provides genetic diagnostics of rare diseases based on Next-Generation Sequencing (NGS). The professional genetic tests are targeted for hospitals and research groups. Blueprint Genetics aims to disrupt the market by decreasing the price level of genetic diagnostics significantly while increasing quality and adding clinical insight to the results statements. The tests are based on a novel NGS method called OS-Seq:tm: that was developed in the Stanford University. The product roadmap of the company covers a long list of diagnostics for different hereditary diseases. The currently available products cover relevant rare hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases. The company is based in Helsinki, Finland and has an office also in Los Angeles, CA.

Blueprint Genetics provides genetic diagnostics of rare diseases based on Next-Generation Sequencing (NGS). The professional genetic tests are targeted for hospitals and research groups. Blueprint Genetics aims to disrupt the market by decreasing the price level of genetic diagnostics significantly while increasing quality and adding clinical insight to the results statements. The tests are based on a novel NGS method called OS-Seq:tm: that was developed in the Stanford University. The product roadmap of the company covers a long list of diagnostics for different hereditary diseases. The currently available products cover relevant rare hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases. The company is based in Helsinki, Finland and has an office also in Los Angeles, CA.